Abstract: A P2X3 and/or P2X2/3 receptor antagonist of formula (I), a pharmaceutical composition comprising the same, and a use thereof in preparing a drug for preventing or treating a disease mediated by the P2X3 and/or P2X2/3 receptor antagonist.

Abstract: Provided herein are antibodies, or antigen binding portions thereof, that bind to OX40. Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.

Abstract: Provided herein are antibodies, or antigen binding portions thereof, that bind to OX40. Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.

Abstract: The present disclosure provides isolated monoclonal antibodies (e.g., humanized and human monoclonal antibodies), or antigen-binding fragments thereof, that specifically bind to human natural killer cell inhibitory receptor group 2A (NKG2A) protein with high affinity and exhibit therapeutically desirable functional properties, such as for the treatment of, for example, cancer. Immunoconjugates, bispecific molecules, and pharmaceutical compositions comprising the anti-NKG2A antibodies of the invention are also provided. Nucleic acid molecules encoding the antibodies, expression vectors, host cells, and methods of treatment of, for example, cancer using the antibodies are further provided. Combination therapy, in which an anti-NKG2A antibody in the present disclosure is co-administered with at least one additional agent such as another antibody (e.g., anti-PD-1, anti-PD-L1, and/or anti-CTLA-4 antibodies), is also provided.

Abstract: The present disclosure provides isolated monoclonal antibodies (e.g., humanized and human monoclonal antibodies), or antigen-binding fragments thereof, that specifically bind to human natural killer cell inhibitory receptor group 2A (NKG2A) protein with high affinity and exhibit therapeutically desirable functional properties, such as for the treatment of, for example, cancer. Immunoconjugates, bispecific molecules, and pharmaceutical compositions comprising the anti-NKG2A antibodies of the invention are also provided. Nucleic acid molecules encoding the antibodies, expression vectors, host cells, and methods of treatment of, for example, cancer using the antibodies are further provided. Combination therapy, in which an anti-NKG2A antibody in the present disclosure is co-administered with at least one additional agent such as another antibody (e.g., anti-PD-1, anti-PD-L1, and/or anti-CTLA-4 antibodies), is also provided.

Abstract: The present disclosure provides isolated monoclonal antibodies (e.g., humanized and human monoclonal antibodies), or antigen-binding fragments thereof, that specifically bind to human natural killer cell inhibitory receptor group 2A (NKG2A) protein with high affinity and exhibit therapeutically desirable functional properties, such as for the treatment of, for example, cancer. Immunoconjugates, bispecific molecules, and pharmaceutical compositions comprising the anti-NKG2A antibodies of the invention are also provided. Nucleic acid molecules encoding the antibodies, expression vectors, host cells, and methods of treatment of, for example, cancer using the antibodies are further provided. Combination therapy, in which an anti-NKG2A antibody in the present disclosure is co-administered with at least one additional agent such as another antibody (e.g., anti-PD-1, anti-PD-L1, and/or anti-CTLA-4 antibodies), is also provided.

Abstract: Provided herein are antibodies, or antigen binding portions thereof, that bind to OX40. Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.

Abstract: Described herein are vectors and methods that are useful for screening variable region sequences of antigen binding molecules with high efficiency. Such vectors rely on the native translation initiation sequences of the variable regions to drive the expression of both the variable region and a reporter gene in the vector.

Abstract: The present disclosure provides isolated monoclonal antibodies (e.g., humanized and human monoclonal antibodies), or antigen-binding fragments thereof, that specifically bind to human natural killer cell inhibitory receptor group 2A (NKG2A) protein with high affinity and exhibit therapeutically desirable functional properties, such as for the treatment of, for example, cancer. Immunoconjugates, bispecific molecules, and pharmaceutical compositions comprising the anti-NKG2A antibodies of the invention are also provided. Nucleic acid molecules encoding the antibodies, expression vectors, host cells, and methods of treatment of, for example, cancer using the antibodies are further provided. Combination therapy, in which an anti-NKG2A antibody in the present disclosure is co-administered with at least one additional agent such as another antibody (e.g., anti-PD-1, anti-PD-L1, and/or anti-CTLA-4 antibodies), is also provided.

Abstract: Provided herein are antibodies, or antigen binding portions thereof, that bind to OX40. Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.

Abstract: Variant antibodies having cysteine substitutions at selected positions in the Fc region can be conjugated via the thiol group of the substituted-in cysteine.

Abstract: Provided herein are antibodies, or antigen binding portions thereof, that bind to OX40. Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.

Abstract: An information interaction method and an electronic device are provided. The method is applicable in a first electronic device. The first electronic device includes a first interaction unit and a second interaction unit, where the first interaction unit includes a first display unit. The method includes receiving device information of a second electronic device via the second interaction unit when the second interaction unit is in a working state; processing the device information of the second electronic device; and sending a procedure of the processing to the first interaction unit via the second interaction unit for displaying via the first display unit. When the second interaction unit is in a working state, the second interaction unit receives device information of the second electronic device, and the connection with the second electronic device may be achieved without inputting information manually, therefore the connection process is simple.

Abstract: The present invention provides a display module (100; 200) and an electronic terminal. The display module (100; 200) comprises: a first display unit (130; 240) configured to display first image information in a first direction; a second display unit (140; 250) configured to display second image information in a second direction; and a sensor unit (150; 260) provided between the first display unit (130; 240) and the second display unit (140; 250) and configured to sense an object's approach or touch on the first display unit (130; 240) and/or the second display unit (140; 250). With the display module (100; 200), the object's approach or touch on the first display unit (130; 240) and the second display unit (140; 250) can be sensed by a single sensor unit (150; 260). There is no need to provide a sensor unit (150; 260) for each of the display units (130; 240; 140; 250) for touch sensing function.

Abstract: A method for identifying input information, an apparatus for identifying input information and an electronic device are provided. The method for identifying input information is applied to an electronic device. The electronic device includes a first panel and a second panel, and further includes a collimated light generator arranged on the first panel and two or more optical detection devices arranged on the first panel. In the method, firstly an information input operation is acquired; then a variation of shadow of the information input operation blocking collimated light beams generated by the collimated light generator is acquired via the optical detection device; and the input information corresponding to the information input operation is acquired according to the variation of shadow.

Abstract: Provided herein are antibodies, or antigen binding portions thereof, that bind to OX40. Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.

Abstract: The invention discloses an information control method and an electronic device. The information control method is applied to a first electronic device, and the first electronic device is connected with a second electronic device. The method includes: detecting feature information of the first electronic device according to a connection relation between the first electronic device and the second electronic device; and controlling the first electronic device according to the feature information.

Abstract: Provided herein are antibodies, or antigen binding portions thereof, that bind to OX40. Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.

Abstract: Provided herein are antibodies, or antigen binding portions thereof, that bind to OX40. Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.

Abstract: The present invention provides an electronic apparatus and an electronic system. The electronic apparatus includes: at least one programmable electric conductive unit configured to switch a good conductor mode and a normal conductor mode according to a control signal when it contacts with a second electronic apparatus so as to transmit predetermined information to the second electronic apparatus contacting with the electronic apparatus; a control unit configured generate the control signal having a predetermined frequency; and a feedback information receiving unit configured to receive feedback information transmitted by the second electronic apparatus, the feedback information being transmitted in response to the reception of the predetermined information.